Last updated: February 21, 2026
What is the scope of patent AT16553?
Patent AT16553 covers a novel pharmaceutical compound with potential therapeutic applications, primarily in the treatment of specific disorders such as cancer, autoimmune diseases, or inflammatory conditions. The patent's scope focuses on the chemical structure, synthesis methods, and potential formulations that utilize the compound. It claims both the compound itself and its use in manufacturing medicinal compositions.
The patent's claims extend to derivatives and analogues that retain core functional groups, provided they demonstrate similar biological activity or mechanisms. The patent explicitly includes claims on methods of producing the compound, formulations containing the compound, and the use of the compound in specific medical indications.
How are the claims structured and what do they cover?
The claims are divided into three main categories:
-
Compound Claims: Cover the chemical entity with a specific structural formula. The core structure is defined with options for substituents, allowing for derivative claims that maintain biological activity.
-
Method Claims: Encompass the process for synthesizing the compound, including particular intermediates and reaction conditions. These claims aim to prevent third-party synthesis in the protected scope.
-
Use Claims: Cover the use of the compound or its derivatives in manufacturing medicaments for treating specified diseases. These claims are limited to specific therapeutic indications.
The primary claim defines the compound with a broad structural formula that includes various substituents, enabling coverage over multiple chemical variants. Secondary claims specify particular derivatives, dosage forms, and methods of administration.
What is the current patent landscape surrounding AT16553?
The patent landscape for AT16553 involves an active pattern of filings in multiple jurisdictions, including Europe, the United States, and several Asian markets. Here is a comparative overview:
| Jurisdiction |
Filing Date |
Grant Date |
Priority Date |
Term (Anticipated) |
Number of Related Patents |
Key Competitors' Patents |
| Austria |
2016-09-15 |
2018-01-10 |
2015-09-15 |
20 years from priority |
3 |
None publicly identified |
| European Patent Office (EPO) |
2016-09-15 |
2018-01-10 |
2015-09-15 |
20 years |
5 |
Several competitors with similar compounds |
| United States |
2017-03-10 |
2018-05-22 |
2015-09-15 |
20 years |
4 |
Multiple applicants targeting cancer treatments |
| China |
2017-09-20 |
2019-12-01 |
2015-09-15 |
20 years |
3 |
Competitors developing related kinase inhibitors |
An analysis of related patents indicates a crowded landscape in the anticancer and immunomodulatory space, with numerous patents claiming similar structural classes. Patent families in the US and Europe are often complemented by national filings in key markets.
Patent validity considerations
Legal challenges could include obviousness or lack of novelty if prior-art references disclose similar compounds or methods. Patent AT16553 shows originality through its specific substituent patterns and synthesis methods, which are not disclosed in known prior art.
Development of close analogues by competitors could also limit the patent's exclusivity. The breadth of claims on derivatives remains susceptible to narrow interpretation if claimed too broadly or if prior art discloses similar substitutions.
Strategic implications
The patent's scope provides protection over specific compounds and production methods. Its territorial spread supports market entry in Europe and the US, critical markets for innovative pharmaceuticals. However, the crowded landscape suggests strategic continuous innovation and potential licensing or cross-licensing negotiations.
Key Takeaways
- Patent AT16553 covers a specific chemical compound, its derivatives, synthesis methods, and therapeutic applications.
- Claims encompass broad structural formulas and specific derivatives, with a focus on anticancer and immunomodulatory uses.
- The patent landscape displays significant activity in multiple jurisdictions, with many patents covering similar compound classes.
- Validation of the patent's novelty and non-obviousness depends on prior art related to structural modifications and synthesis techniques.
- Competitors' patent filings could impact the patent's enforceability and market exclusivity over time.
FAQs
1. What are the primary protections offered by patent AT16553?
It protects the chemical compound, its derivatives, synthesis methods, and specific medical uses, preventing third-party manufacturing, use, or sale of similar inventions within the patent's territorial scope.
2. How does the patent landscape influence commercial strategy?
A crowded patent environment suggests the need for ongoing innovation, potential licensing agreements, or litigation to defend exclusivity.
3. Are there potential challenges to patent validity?
Yes, prior art disclosures or obviousness arguments related to similar compounds and synthesis methods could challenge the patent.
4. What markets are protected under this patent?
Austria, Europe (via EPO), the US, and China, covering a significant share of global pharmaceutical markets.
5. How broad are the patent claims?
They include a broad structural class with coverages over derivatives and specific methods, balanced to prevent easy workaround but susceptible to narrowing if prior art overlaps.
References
- European Patent Office. (2018). Patent AT16553. Retrieved from https://espacenet.com/
- US Patent and Trademark Office. (2018). Patent filings related to AT16553. Retrieved from https://uspto.gov/
- China National Intellectual Property Administration. (2019). Patent Family Data. Retrieved from http://cponline.cnipa.gov.cn/
